David D Davidar

Director David D Davidar sold 25,000 shares of GMED at $80.76 for $2.0M on 2026-06-05, retaining 510.2K shares.

David D Davidar, a GMED director, sold 25,000 shares at $80.76, reducing his non-derivative holdings from 535.2K to 510.2K shares (a -4.7% decrease). GMED's fundamentals remain solid with revenue of $759.9M and net income of $124.3M in the latest quarter, alongside annual revenue growth of +16.6%. Davidar maintains a substantial residual position of 510.2K shares post-transaction, indicating continued significant direct investment in the company. His cross-ticker track record shows 9 prior sells; however, none of his prior same-ticker transactions at GMED have yet reached measurable 90-day outcome points, limiting inference about his timing accuracy at this specific stock. The sale appears consistent with a partial reduction rather than a material change in conviction.

Director David Davidar sold 25,000 GMED shares at $86.00 for $2.2M; strong prior timing at same ticker with 4 of 5 sells well-timed at 90-day mark.

Director David Davidar sold 25,000 shares (25.0K shares) of GLOBUS MEDICAL INC (GMED) at $86.00 on 2025-11-12, reducing holdings by 4.6% to 516,275 shares. The stock has appreciated significantly over 30 and 90 days (+44.6% and +38.7% respectively), trading near its 52-week high. Notably, his prior trades at GMED show a strong timing pattern: 4 of 5 prior sells were well-timed at the 90-day mark, with three consecutive sales on 2024-11-21 and 2024-11-22 each followed by -2.8% and -1.0% to -1.1% 90-day returns. This sell occurs when the stock is positioned in the upper portion of its annual trading range and after a sustained multi-month rally, consistent with his demonstrated pattern of selling into strength at this particular ticker.

Director David D sold 40,000 GMED shares at $85.00 across 4 transactions for $3.4M on Nov 21-22.

David D, a director, executed 4 separate sales totaling 40,000 shares for $3,400,049.99 at an average price of $85.00, reducing his holdings by 19.4% from 205,967 shares to 165,967 shares. The timing is notable: the sales occurred within one day of the stock's 52-week high of $84.91, and the stock has since declined 0.5% to $84.49, suggesting the director sold near peak levels. His track record at GMED shows limited measurable outcomes on recent sales (two October sales with 30-day returns of +8.1% each, and a September sale with 0.2%), though his cross-ticker history spans 4 prior sells with an average 90-day return of +6.2% but a 0% well-timed rate (meaning his cross-ticker sells have generally been followed by stock appreciation, not declines). The multi-transaction structure and the magnitude (40K shares) indicate a deliberate execution, though the fundamental backdrop shows strong growth (revenue up 53.3% year-over-year) and sustained profitability of $51.8M, which may contextualize the sale within normal portfolio activity rather than distress signaling.

Director Davidar David D sold 50,000 shares at $75.04 blended avg on 2024-10-16 for $3.8M, reducing GMED stake by 21.2%

Director Davidar David D executed 2 separate sales totaling 50,000 shares for $3,751,813.00 at a blended average price of $75.04, reducing his position from 236,000 to 186,000 shares (a 21.2% reduction). The sales occurred near the 52-week high ($74.88), with the stock currently trading at $72.85. At this ticker, his prior 2 sales generated mixed returns: a May 2024 sale posted +6.2% at 90 days, while a September 2024 sale is still within its 90-day window. His cross-ticker track record shows 2 prior sales with a 0.00% well-timed rate at 90 days, indicating those trades were poorly timed (stock rose after). The company trades at a P/E of 242.83 with revenue growth of +53.3% year-over-year, though post-transaction holdings of 185,967 shares remain material. The magnitude and timing merit monitoring for follow-on activity.

Director Davidar David sold 25,000 GMED shares at $70.46 on 2024-09-13; holds 566,275 shares post-sale.

Davidar David, a director, sold 25,000 shares (25.0K shares) of GLOBUS MEDICAL INC (GMED) at $70.46 on 2024-09-13 for a total value of $1,761,500.00 ($1.8M), reducing his holdings from 591,275 shares to 566,275 shares. This represents a -4.2% reduction in his position. At his prior sale of GMED shares on 2024-05-08, the stock subsequently returned +6.2% over 90 days, indicating his prior sales at this ticker have not aligned with downturns. The current stock price of $69.34 is -6.2% below the 52-week high of $73.92 and has declined -0.7% over the last 30 days, though it is up +3.5% over 90 days. The company's fundamentals show strong growth with annual revenue growth of +53.3%, though the P/E ratio of 231.13 reflects elevated valuation expectations relative to current earnings of $31,760,000.00 ($31.8M) on revenue of $629,691,000.00 ($629.7M).